Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
Index- P/E18.75 EPS (ttm)3.71 Insider Own0.00% Shs Outstand166.53M Perf Week1.98%
Market Cap11.58B Forward P/E18.38 EPS next Y3.79 Insider Trans- Shs Float166.44M Perf Month6.23%
Income617.96M PEG89.30 EPS next Q0.76 Inst Own13.94% Short Float / Ratio0.64% / 4.31 Perf Quarter2.26%
Sales3.24B P/S3.57 EPS this Y10.82% Inst Trans4.66% Short Interest1.06M Perf Half Y22.67%
Book/sh18.31 P/B3.80 EPS next Y3.56% ROA15.94% Target Price67.30 Perf Year23.57%
Cash/sh4.91 P/C14.16 EPS next 5Y0.21% ROE22.14% 52W Range51.11 - 73.17 Perf YTD34.45%
Dividend0.47 P/FCF16.09 EPS past 5Y29.78% ROI19.80% 52W High-4.91% Beta0.55
Dividend %0.68% Quick Ratio1.91 Sales past 5Y6.90% Gross Margin56.50% 52W Low36.14% ATR0.95
Employees25863 Current Ratio2.59 Sales Q/Q5.33% Oper. Margin23.04% RSI (14)65.33 Volatility1.02% 1.24%
OptionableYes Debt/Eq0.05 EPS Q/Q28.12% Profit Margin19.07% Rel Volume1.21 Prev Close69.90
ShortableYes LT Debt/Eq0.02 EarningsOct 27 AMC Payout12.14% Avg Volume246.35K Price69.58
Recom2.58 SMA204.67% SMA504.88% SMA20011.54% Volume299,086 Change-0.46%
Date Action Analyst Rating Change Price Target Change
Aug-29-23Downgrade HSBC Securities Buy → Hold
May-18-23Downgrade Bernstein Outperform → Mkt Perform
Mar-17-23Upgrade BofA Securities Neutral → Buy
Jan-30-23Initiated JP Morgan Underweight
Nov-14-22Downgrade Credit Suisse Neutral → Underperform
Jan-03-22Resumed BofA Securities Neutral
Jul-27-21Downgrade Credit Suisse Outperform → Neutral
Feb-02-21Upgrade Barclays Equal Weight → Overweight $56 → $70
Sep-18-20Upgrade Investec Sell → Hold
Sep-18-20Upgrade BofA Securities Neutral → Buy
Nov-02-23 09:40AM
Oct-30-23 07:38AM
Oct-29-23 01:08PM
Oct-27-23 02:13PM
12:00PM Loading…
Oct-26-23 12:00PM
Oct-04-23 12:45PM
Sep-26-23 09:35AM
Sep-18-23 12:45PM
Aug-31-23 12:45PM
Aug-10-23 07:00AM
Jul-28-23 08:02AM
Jul-27-23 10:30AM
Jul-26-23 12:31PM
Jul-12-23 10:25AM
09:45PM Loading…
Jun-09-23 09:45PM
Jun-08-23 09:54PM
Jun-06-23 07:18AM
Jun-05-23 07:00AM
Jun-04-23 03:51PM
May-16-23 10:22AM
May-11-23 09:58AM
May-10-23 11:43AM
May-08-23 01:28PM
May-05-23 07:17AM
Apr-21-23 07:15AM
Mar-20-23 07:00AM
Feb-27-23 03:04PM
06:00AM Loading…
Feb-08-23 08:50AM
Jan-31-23 06:25PM
Jan-30-23 06:51PM
Jan-27-23 01:36PM
Jan-26-23 12:55PM
Jan-20-23 06:30AM
Dec-19-22 08:00AM
Oct-31-22 11:01AM
Oct-11-22 07:57AM
Sep-07-22 01:28PM
Aug-17-22 10:16AM
Aug-02-22 09:45AM
Jul-29-22 04:28PM
Jul-27-22 03:26AM
Jul-22-22 06:17AM
Jul-08-22 11:48AM
Jul-05-22 03:30AM
Jun-24-22 09:45AM
Jun-14-22 02:51AM
May-27-22 10:15AM
May-24-22 01:40PM
May-20-22 09:50AM
Apr-20-22 12:41PM
Apr-05-22 06:52AM
Apr-01-22 08:00AM
Mar-27-22 01:09AM
Feb-09-22 09:17AM
Feb-03-22 09:33AM
Feb-02-22 04:15AM
Jan-31-22 01:10PM
Jan-04-22 06:18AM
Dec-15-21 01:49PM
Dec-14-21 12:20PM
Dec-09-21 11:47PM
Dec-08-21 09:00PM
Nov-16-21 07:33AM
Nov-01-21 11:50AM
Oct-29-21 08:59AM
Oct-19-21 12:14AM
Oct-15-21 01:40PM
Sep-09-21 08:30AM
Sep-07-21 07:30AM
Sep-04-21 01:11AM
Sep-02-21 12:12AM
Aug-31-21 02:43AM
Aug-18-21 08:30AM
Aug-04-21 10:32AM
Aug-03-21 08:32AM
Jul-29-21 04:00PM
Jul-27-21 12:38PM
Jun-30-21 11:58PM
Jun-29-21 11:30AM
Jun-22-21 02:07AM
Jun-03-21 10:00AM
May-17-21 12:17PM
May-12-21 12:56AM
May-11-21 06:03AM
Apr-29-21 10:41AM
Apr-13-21 06:57AM
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.